Company intelligence / Profile preview

Magnus Medical

Burlingame, California, United Statesmagnusmed.com ↗

Ownership: Private
Development stage: Commercial

Overview

The SAINT neuromodulation system has demonstrated rapid and durable antidepressant effects in adults with treatment-resistant major depressive disorder. In a double-blind RCT, remission rates were reported at approximately 79% for active treatment versus 13% for sham. Open-label studies show remission rates of ~80–90%. New data presented in August 2024 indicate sustained benefits with an average of eleven weeks' remission after a single five-day course.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapy (neuromodulation)Electromagnetic stimulation
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SAINT neuromodulation system

Commercial

Indications: Treatment-resistant Major Depressive Disorder

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Magnus Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnus Medical.

Explore the full profile